Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst Downgrade

Posted by on Sep 18th, 2026

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report)’s share price gapped down prior to trading on Friday after Royal Bank Of Canada lowered their price target on the stock from $81.00 to $70.00. The stock had previously closed at $57.35, but opened at $44.02. Royal Bank Of Canada currently has an outperform rating on the stock. Xenon Pharmaceuticals shares last traded at $40.6950, with a volume of 4,216,082 shares.

XENE has been the subject of a number of other research reports. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Robert W. Baird reduced their price objective on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Needham & Company LLC cut their target price on shares of Xenon Pharmaceuticals from $78.00 to $60.00 and set a “buy” rating for the company in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $46.00 price target (down from $90.00) on shares of Xenon Pharmaceuticals in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $70.93.

View Our Latest Stock Analysis on XENE

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director owned 1,870 shares of the company’s stock, valued at approximately $119,792.20. This trade represents a 84.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Christopher Kenney sold 7,068 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the sale, the insider owned 2 shares of the company’s stock, valued at approximately $120.50. This represents a 99.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.91% of the company’s stock.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

  • Positive Sentiment: Xenon submitted a New Drug Application to the FDA for azetukalner in focal seizures, a major regulatory milestone that could support the drug’s first potential commercial indication. Xenon NDA submission announcement
  • Positive Sentiment: Despite reducing their valuation assumptions, Wedbush, Robert W. Baird, and Needham retained bullish ratings of “outperform” or “buy.” Their revised targets still indicate substantial potential upside from the current trading level: $55, $90, and $60, respectively. Analyst actions on Xenon Pharmaceuticals
  • Neutral Sentiment: The FDA filing advances azetukalner’s focal-seizure program, while the company’s broader psychiatry strategy is being reassessed following reported adverse events involving mental and nervous-system symptoms. Xenon clinical program update transcript
  • Negative Sentiment: Xenon temporarily halted new enrollment in depression and bipolar-disorder trials after adverse events were reported. The pause raises safety, timing, and commercial-viability risks for azetukalner’s psychiatric opportunity and prompted the sharp decline in XENE shares. Reuters report on Xenon trial pause
  • Negative Sentiment: Analysts lowered their price targets substantially, signaling reduced confidence in the company’s near-term risk-reward profile even though their overall ratings remain positive. Xenon stock market update

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter valued at $6,813,000. BlackRock Inc. acquired a new position in Xenon Pharmaceuticals during the 2nd quarter valued at about $454,057,000. Siren L.L.C. raised its stake in Xenon Pharmaceuticals by 62.2% in the first quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company’s stock valued at $76,674,000 after buying an additional 505,803 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Xenon Pharmaceuticals by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company’s stock valued at $23,035,000 after buying an additional 8,980 shares during the last quarter. Finally, Nicholas Investment Partners LP boosted its holdings in Xenon Pharmaceuticals by 104.0% in the fourth quarter. Nicholas Investment Partners LP now owns 242,989 shares of the biopharmaceutical company’s stock worth $10,891,000 after acquiring an additional 123,891 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Price Performance

The firm has a market cap of $3.99 billion, a price-to-earnings ratio of -8.67 and a beta of 0.61. The firm has a fifty day simple moving average of $62.70 and a two-hundred day simple moving average of $58.07.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same quarter last year, the company posted ($1.07) EPS. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its expertise in ion channels, which regulate the electrical activity of nerve cells, to discover and advance potential treatments for conditions with significant unmet medical needs.

Xenon’s leading investigational product is azetukalner (XEN1101), an oral, small-molecule potassium-channel opener being studied in epilepsy, including focal-onset seizures, and major depressive disorder.

Featured Stories

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.